RNA Jun 2024 15.000 call
| Previous close | 13.15 |
| Open | 13.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 15.00 |
| Expiry date | 2024-06-21 |
| Day's range | 13.15 - 13.15 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireAvidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and one poster presentation at the 31st Annual FSHD Society International Research Congress, being held June 13-14, 2024, in Denver, Colorado.
- PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,500 shares of its common stock and 33,250 restricted stock units ("RSUs") to seven (7) new non-executive employees under the Avidity Bioscie
PR NewswireAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatm
